Skip to main content
profileAnalyst coverage5 yr. financialspremium researchdividendsadv. chartsearningsoptionsprice historyeventsinsiders

ZIOPHARM Oncology, Inc. News

Why 2018 will be better for biotech deals than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Immunotherapy stocks power higher on Celgene-Juno deal

Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.

More Immunotherapy Buyouts Likely After Kite Sale

More Immunotherapy Buyouts Likely After Kite Sale

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

Breaking News

Stock Market Today - 6/29: Stocks End Mixed As Recession Concerns Mount

Stocks ended mixed Wednesday as growth bets gave way to recession fears.

Should I Buy a House Now? (June 2022)

Mortgage rates are up and some markets have cooled down, but the reality is that the decision is very personal.

Crypto Crash Exposes Robinhood and Coinbase To Predators

A year can be a lifetime in the cryptocurrency world as major players are reeling from heavy losses.

Micron Earnings Preview: Will Critical Support Hold?

Micron is set to report earnings on Thursday after the close, but the stock sits on critical support. Will it hold or will it fold?